AI Analysis | Feedback

• Acadia Pharmaceuticals for sleep and broader psychiatric disorders.
• Vertex Pharmaceuticals, but focused on neurological and sleep disorders instead of cystic fibrosis.

AI Analysis | Feedback

• HETLIOZ: A marketed therapy for the treatment of non-24-hour sleep-wake disorders.
• Fanapt: Marketed oral tablets for the treatment of schizophrenia.
• Tradipitant (VLY-686): A small molecule neurokinin-1 receptor antagonist in development for atopic dermatitis, gastroparesis, and motion sickness.
• VTR-297: A small molecule histone deacetylase inhibitor under development for hematologic malignancies and other oncology indications.
• VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist being developed for psychiatric disorders.
• HETLIOZ (tasimelteon) extended indications: Investigated for new conditions including jet lag disorder, smith-magenis syndrome, and autism spectrum disorders.
• Fanapt (iloperidone) extended indications/formulations: Explored for new indications such as bipolar disorder and as a long-acting injectable formulation for schizophrenia.

AI Analysis | Feedback

Vanda Pharmaceuticals Inc. (VNDA) primarily sells its pharmaceutical products to individual patients through the healthcare system.

Its major customer categories are:

• Individuals diagnosed with non-24-hour sleep-wake disorder, who are prescribed HETLIOZ.
• Individuals diagnosed with schizophrenia, who are prescribed Fanapt oral tablets.

AI Analysis | Feedback

Thermo Fisher Scientific (TMO)

Catalent, Inc. (CTLT)

Norwich Pharmaceuticals, Inc.

AI Analysis | Feedback

Mihael H. Polymeropoulos, MD, President, Chief Executive Officer and Chairman of the Board

Mihael H. Polymeropoulos cofounded Vanda Pharmaceuticals in 2003 and has served as President, Chief Executive Officer, and a Director since May 2003, and as Chairman of the Board since June 2021. Prior to Vanda, he was Vice President and Head of the Pharmacogenetics Department at Novartis AG from 1998 to 2003, and Chief of the Gene Mapping Section at the National Human Genome Research Institute from 1992 to 1998. He is also a cofounder of the Integrated Molecular Analysis of Genome Expression (I.M.A.G.E.) Consortium. Vanda was founded in partnership with Care Capital LLC, a biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government, indicating private equity backing at the company's inception.

Kevin Moran, Senior Vice President, Chief Financial Officer and Treasurer

Kevin Moran has served as Vanda's Senior Vice President, Chief Financial Officer and Treasurer since July 2020. He joined Vanda in September 2010 and held various finance roles, including Controller, Vice President and Controller, and Vice President, Acting Chief Financial Officer and Treasurer, before his current appointment. Before joining Vanda, Mr. Moran was a Senior Associate at PricewaterhouseCoopers. He earned his Bachelor of Business Administration and Master of Science in Accounting from James Madison University.

Gunther Birznieks, Senior Vice President, Business Development

Gunther Birznieks is Vanda's Senior Vice President, Business Development, and a member of the R&D Committee. He has held various positions at Vanda since 2003, including Clinical Program Head of the Hetlioz and VSF-173 programs, Head of Informatics, and Head of Operations in Singapore. Prior to Vanda, Mr. Birznieks founded Extropia Pte Ltd, a Singaporean company focused on business and investment banking applications. His career also includes work in healthcare and biomedical informatics, providing bioinformatics support for the Human Genome Project.

Tim Williams, Senior Vice President, General Counsel and Secretary

Tim Williams has served as Vanda's Senior Vice President, General Counsel, and Secretary since August 2018. Before joining Vanda, he was Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at AgNovos Healthcare, a medical device company. Previously, Mr. Williams was Senior Legal Counsel and Assistant Secretary at Stryker Corporation, a global medical technology company, where he led global M&A, corporate governance, and securities groups. He also practiced law at Mayer Brown LLP and Bryan Cave LLP.

Joakim Wijkstrom, Senior Vice President, Chief Marketing Officer

Joakim Wijkstrom, also known as Kim Wijkstrom, has served as Vanda's Senior Vice President, Chief Marketing Officer, since August 2019. Prior to Vanda, he held Chief Marketing Officer positions at Perry Ellis International and OneMain Financial. He also held senior leadership roles at advertising agencies such as TBWA Chiat Day, BBDO, and Crispin Porter + Bogusky, where he developed marketing strategies for various clients including Apple and Volkswagen. Mr. Wijkstrom holds a BA in Art History from Georgetown University and an MBA in Marketing from New York University.

AI Analysis | Feedback

Key Risks to Vanda Pharmaceuticals (VNDA):

1. Clinical Development and Regulatory Approval Risk: Vanda Pharmaceuticals has an extensive pipeline with numerous product candidates and indications under development, including further applications for HETLIOZ and Fanapt, as well as several novel compounds like Tradipitant, VTR-297, and VQW-765. The success of a biopharmaceutical company heavily relies on the successful outcome of costly and lengthy clinical trials and subsequent regulatory approvals. Failures in late-stage clinical trials due to lack of efficacy or safety concerns, or an inability to obtain regulatory marketing authorization, would significantly impact the company's future growth and financial performance, as a substantial portion of its future value is tied to the successful commercialization of these pipeline assets.
2. Reliance on a Limited Number of Marketed Products: Vanda Pharmaceuticals currently generates revenue primarily from two marketed products: HETLIOZ for non-24-hour sleep-wake disorders and Fanapt oral tablets for schizophrenia. Any significant adverse events, unexpected safety concerns, manufacturing issues, or changes in reimbursement policies affecting these two products could severely impact the company's revenue stream and profitability, given its current dependence on them.
3. Intense Competition for Marketed Products: Both the sleep disorder and schizophrenia markets are competitive. HETLIOZ, while addressing a niche disorder, and Fanapt face competition from existing treatments, and potential new entrants could further intensify this landscape. Competitive pressures, including the introduction of new, more effective, or lower-cost therapies, could lead to reduced market share, pricing pressure, and decreased demand for Vanda's current commercialized products.

AI Analysis | Feedback

AI Analysis | Feedback

Addressable Markets for Vanda Pharmaceuticals' Main Products

For Vanda Pharmaceuticals' key products and their indications, the addressable market sizes are as follows:

HETLIOZ (tasimelteon)

• Non-24-hour sleep-wake disorders: The global market size was valued at USD 1.5 billion in 2024 and is expected to reach USD 3.2 billion by 2032.
• Smith-Magenis syndrome: The global market size was valued at USD 120 million in 2024 and is expected to reach USD 192.71 million by 2032.
• Delayed sleep phase disorder: This falls under the global circadian rhythm sleep treatment market, which is valued at US$ 2.4 billion in 2025 and is projected to reach US$ 3.7 billion by 2032.
• Jet lag disorder: This is part of the global circadian rhythm sleep treatment market, estimated at US$ 784.7 million in 2024 and projected to reach US$ 1.23 billion by the end of 2034.
• Pediatric Non-24: null
• Autism spectrum (sleep-related): null

Fanapt (iloperidone)

• Schizophrenia: The global market size was estimated at USD 8.36 billion in 2024 and is expected to reach USD 12.78 billion by 2032. The U.S. market was valued at USD 2.84 billion in 2024 and is projected to reach USD 4.31 billion by 2032.
• Bipolar disorder: The global market size was valued at USD 5.7 billion in 2024 and is projected to grow to USD 8.2 billion by 2034. The U.S. market is projected to reach USD 3.5 billion by 2034.

Tradipitant (VLY-686)

• Atopic dermatitis: The global market size was estimated at USD 17.64 billion in 2024 and is projected to reach USD 29.88 billion by 2030. The U.S. market generated a revenue of USD 6,405.7 million in 2024 and is expected to reach USD 9,991.8 million by 2030.
• Gastroparesis: The global market size was valued at USD 6.82 billion in 2024 and is expected to reach USD 9.89 billion by 2032. The U.S. gastroparesis treatment market size was exhibited at USD 1.95 billion in 2024 and is projected to be worth around USD 3.13 billion by 2034.
• Motion sickness: The global motion sickness treatment market size was USD 719.69 million in 2024 and is projected to reach USD 922.53 million by 2032.

AI Analysis | Feedback

Here are the expected drivers of future revenue growth for Vanda Pharmaceuticals (VNDA) over the next 2-3 years:

1. Expanded Market Penetration and Indications for Fanapt: Vanda Pharmaceuticals anticipates continued revenue growth from Fanapt (iloperidone) through increased market penetration in its approved indications of schizophrenia and, notably, bipolar I disorder, for which it launched in April 2024. This growth is evidenced by a 24% increase in full-year 2025 net product sales, driven by a 28% rise in total prescriptions and a significant 149% surge in new-to-brand prescriptions. Strategic sales and marketing efforts, including direct-to-consumer campaigns, are expected to further enhance brand awareness and prescriber engagement, contributing an estimated $150-$170 million in 2026.
2. Launch of Bysanti (milsaperidone): The recent FDA approval of BYSANTI (milsaperidone) for the treatment of bipolar I disorder and schizophrenia, announced in February 2026, is a key driver for future revenue. With a PDUFA target action date of February 21, 2026, and an anticipated launch in Q3 2026, Bysanti benefits from expected long-term market exclusivity extending to 2044, providing a sustained revenue stream.
3. Launch and Pipeline Expansion of NEREUS (tradipitant): The approval of NEREUS (tradipitant) for the prevention of vomiting induced by motion, with a PDUFA date of December 30, 2025, and a potential launch by mid-2026, presents a new commercial opportunity. Furthermore, Vanda plans to initiate a Phase 3 program in the first half of 2026 for NEREUS's use in preventing vomiting from GLP-1 analogs, with results expected by the end of 2026. Positive clinical results in this area indicate significant potential for enhanced compliance and demand in the growing obesity treatment market.
4. Commercialization of PONVORY: The acquisition of PONVORY in Q4 2023 and its subsequent successful commercial launch for multiple sclerosis are expected to contribute to revenue growth. The product has seen increased patient demand throughout 2025 and is projected to contribute to the combined $80-$90 million in revenue from HETLIOZ and PONVORY in 2026.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

• Vanda Pharmaceuticals repurchased $0.92 million in common stock in fiscal year 2025.
• No significant share repurchases were reported for fiscal years 2021, 2022, 2023, or 2024.

Share Issuance

• The company issued $3.55 million in common stock in fiscal year 2021.
• Vanda Pharmaceuticals issued $0.73 million in common stock in fiscal year 2022.
• In February 2026, Vanda Pharmaceuticals filed a shelf registration to offer up to $200 million in various securities, including common stock, for future capital raising.

Outbound Investments

• Vanda Pharmaceuticals made a significant investment in intangible assets, amounting to $100.67 million, in fiscal year 2023.
• The company purchased $4.23 million in intangible assets in fiscal year 2024.

Capital Expenditures

• Annual capital expenditures were $0.55 million in fiscal year 2021, $0.68 million in fiscal year 2022, $0.38 million in fiscal year 2023, $0.49 million in fiscal year 2024, and $1 million in fiscal year 2025.
• These expenditures are typically focused on maintaining and upgrading operational infrastructure, such as laboratory equipment and information technology.